Arianna Cabrales, Kirsten Fernando, Tim Craven, Emily McCracken, Colleen Jay, Giuseppe Orlando, Alan Farney, Christopher Webb, Amber Reeves-Daniel, Natalia Sakhovskaya, Alejandra Mena-Gutierrez, Robert Stratta
{"title":"Race-Neutral Glomerular Filtration Rate Projected to Increase Kidney Transplantation for Black Patients: Initial Policy Effects at a Single Center.","authors":"Arianna Cabrales, Kirsten Fernando, Tim Craven, Emily McCracken, Colleen Jay, Giuseppe Orlando, Alan Farney, Christopher Webb, Amber Reeves-Daniel, Natalia Sakhovskaya, Alejandra Mena-Gutierrez, Robert Stratta","doi":"10.1111/ctr.70688","DOIUrl":null,"url":null,"abstract":"<p><p>The 2023 organ procurement and transplantation network (OPTN) policy \"Modify waiting time for candidates affected by race-inclusive eGFR calculations\" for kidney transplantation (KT) was analyzed at our kidney transplant center over a 15-month period following its implementation. A total of 372 adult Black patients active on our KT waiting list were identified, of whom 104 (28%) qualified for waiting-time modification (WTM). The WTM group gained a median total waiting time of 2.4 years, with 36 (35%) receiving KTs compared to 107 (42%) in the no wait-time modification (NWTM) group. Pre-listing time, older age, female gender, and A or B blood type was found to increase likelihood of KT in both groups. Despite lower actual transplant rates during the study period, the WTM group is projected to gain a 25% annual probability of transplant for each additional year of qualifying time. Therefore, while the decision to grant WTM has generated some controversy, short-term outcomes at our center suggest that the OPTN policy change has the potential to improve transplant access among Black patients without necessarily disadvantaging those Black patients who do not benefit from WTM. Longer follow-up is required to determine the intended and unintended effects of the race-neutral GFR (rnGFR) and WTM policy changes.</p>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"40 10","pages":"e70688"},"PeriodicalIF":1.8000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ctr.70688","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
The 2023 organ procurement and transplantation network (OPTN) policy "Modify waiting time for candidates affected by race-inclusive eGFR calculations" for kidney transplantation (KT) was analyzed at our kidney transplant center over a 15-month period following its implementation. A total of 372 adult Black patients active on our KT waiting list were identified, of whom 104 (28%) qualified for waiting-time modification (WTM). The WTM group gained a median total waiting time of 2.4 years, with 36 (35%) receiving KTs compared to 107 (42%) in the no wait-time modification (NWTM) group. Pre-listing time, older age, female gender, and A or B blood type was found to increase likelihood of KT in both groups. Despite lower actual transplant rates during the study period, the WTM group is projected to gain a 25% annual probability of transplant for each additional year of qualifying time. Therefore, while the decision to grant WTM has generated some controversy, short-term outcomes at our center suggest that the OPTN policy change has the potential to improve transplant access among Black patients without necessarily disadvantaging those Black patients who do not benefit from WTM. Longer follow-up is required to determine the intended and unintended effects of the race-neutral GFR (rnGFR) and WTM policy changes.
期刊介绍：
Clinical Transplantation: The Journal of Clinical and Translational Research aims to serve as a channel of rapid communication for all those involved in the care of patients who require, or have had, organ or tissue transplants, including: kidney, intestine, liver, pancreas, islets, heart, heart valves, lung, bone marrow, cornea, skin, bone, and cartilage, viable or stored.
Published monthly, Clinical Transplantation’s scope is focused on the complete spectrum of present transplant therapies, as well as also those that are experimental or may become possible in future. Topics include:
Immunology and immunosuppression;
Patient preparation;
Social, ethical, and psychological issues;
Complications, short- and long-term results;
Artificial organs;
Donation and preservation of organ and tissue;
Translational studies;
Advances in tissue typing;
Updates on transplant pathology;.
Clinical and translational studies are particularly welcome, as well as focused reviews. Full-length papers and short communications are invited. Clinical reviews are encouraged, as well as seminal papers in basic science which might lead to immediate clinical application. Prominence is regularly given to the results of cooperative surveys conducted by the organ and tissue transplant registries.
Clinical Transplantation: The Journal of Clinical and Translational Research is essential reading for clinicians and researchers in the diverse field of transplantation: surgeons; clinical immunologists; cryobiologists; hematologists; gastroenterologists; hepatologists; pulmonologists; nephrologists; cardiologists; and endocrinologists. It will also be of interest to sociologists, psychologists, research workers, and to all health professionals whose combined efforts will improve the prognosis of transplant recipients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
